Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid Leukemia
- Interventions
- Drug: AzacitidineDrug: CytarabineDrug: Etoposide PhosphateOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone HydrochlorideOther: Pharmacological Study
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01249430
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT01246622
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 144
- Registration Number
- NCT01237808
- Locations
- 🇩🇪
Ubbo-Emmius Klinik Aurich, Aurich, Germany
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Medizinische Universitätsklinik, Freiburg, Germany
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Therapy-Related Acute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Core Binding Factor Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT01238211
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Heartland Cancer Research NCORP, Decatur, Illinois, United States
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
- Conditions
- Cardiac ToxicityLeukemiaLymphoma
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT01230983
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
- Conditions
- Leukemia
- Interventions
- Drug: AmsacrineDrug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: DexamethasoneDrug: Daunorubicin hydrochlorideDrug: Doxorubicin hydrochlorideDrug: Etoposide phosphateDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: MethylprednisoloneDrug: ThioguanineDrug: Vincristine sulfateRadiation: Whole-brain radiation therapy
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 745
- Registration Number
- NCT01228331
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪University Medical Center Hamburg - Eppendorf, Hamburg, Germany
🇩🇪Johannes Gutenberg University, Mainz, Germany
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3762
- Registration Number
- NCT01225874
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 75
- Registration Number
- NCT01193400
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau., Barcelona, Spain
🇪🇸Hospital Durán i Reynals (Bellvitge)., Barcelona, Spain
🇪🇸Hospital General de Alicante., Alicante, Spain
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Xiaofan Zhu
- Target Recruit Count
- 65
- Registration Number
- NCT01191541
- Locations
- 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China, Tianjin, China
🇨🇳Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
- Conditions
- Ann Arbor Stage I B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaAdult B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Down SyndromeHypodiploid B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveAnn Arbor Stage II B Lymphoblastic LymphomaChildhood B Lymphoblastic Lymphoma
- Interventions
- Drug: DexamethasoneDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: MethotrexateDrug: Doxorubicin HydrochlorideOther: Quality-of-Life AssessmentOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationDrug: Leucovorin CalciumDrug: Vincristine SulfateDrug: PegaspargaseDrug: Thioguanine
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 9350
- Registration Number
- NCT01190930
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.